# Apella Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apella-technology

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.apella.io/
- Total disclosed funding: $24M
- Latest round: Series B (Jan 8, 2026)
- Investors on record: 10

## About

Founded in 2020, Apella Technology Inc. is based in San Francisco, US. The company focuses on optimizing surgical procedures through its advanced platform. The founders include Ben T, Cameron Marlow, Jordan Tuttle, Rajesh Khanduja, and Ritu Khanduja. David Schummers serves as the CEO. In January 2026, Apella Technology Inc. raised series B funding led by HighlandX, with participation from Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, and Operator Partners. K2 HealthVentures, OpAmp Capital, Houston Methodist Hospital Systems, also participated in the round. The round was a part of a larger USD 80 million in series B and venture debt funding.
Apella's core product offering is a real-time operating room management platform that integrates ambient technology, artificial intelligence (AI), and electronic health record (EHR) data to optimize surgical operations. The platform enhances the efficiency of surgical teams by providing operational intelligence, allowing for the elimination of delays and distractions during procedures. Key functionalities include live video access for case monitoring, real-time surgical schedule updates, and automated alerts for coordination across surgical teams. This technology is primarily utilized in hospitals and surgical centers, targeting health systems across the United States and extending to other regions with advanced healthcare infrastructures.
Apella generates revenue through subscription-based services offered to healthcare providers, including hospitals and surgical centers. Clients engage with the platform via annual contracts that provide access to software updates, customer support, and training. Revenue is accrued as institutions subscribe to enhance operational efficiency, with pricing structures reflecting the facility's scale and the number of operating rooms covered. Apella’s platform plays a critical role in helping surgical teams increase case volumes and optimize resource utilization, contributing to improved financial outcomes for healthcare providers. This transactional framework supports a business-to-business relationship, facilitating continuous leveraging of Apella's technology to achieve better operational metrics and patient outcomes.
The company plans to use the January 2026 funding to support commercialization efforts and product development.

## Funding rounds

- Series B, Jan 8, 2026 — Casdin Capital, Houston Methodist Hospital System, Upside Partnership, Vensana Capital, K2 HealthVentures, Operator Partners, PFM Health Sciences, OpAmp Capital, Highlandx
- Series A, Dec 20, 2021, $21M — Casdin Capital, Upside Partnership, Vensana Capital, Operator Partners, Twine Ventures, PFM Health Sciences
- Seed, Apr 1, 2020, $3M — PFM Health Sciences

## Investors

- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Seed, Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Upside Partnership (https://capitalatlas.ai/funds/upside-partnership) — Series A, Series B
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series A, Series B
- Operator Partners — Series A, Series B
- Twine Ventures (https://capitalatlas.ai/funds/twine-ventures) — Series A
- Houston Methodist Hospital System — Series B
- K2 HealthVentures (https://capitalatlas.ai/funds/k2-healthventures) — Series B
- OpAmp Capital (https://capitalatlas.ai/funds/opamp-capital) — Series B
- Highlandx (https://capitalatlas.ai/funds/highlandx) — Series B